Cannabidiol, Morphine, Pain

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wayne State University
• Treatments: Epidiolex; Morphine

Criteria

Inclusion Criteria:

• Participants must report having smoked a cigarette (nicotine or marijuana) AND having taken an opioid > 3 occasions lifetime.

• Participants must be in good health to participate; those with contraindications will be excluded.

• All participants will undergo psychiatric evaluation and will be asked to report their substance use history by interview and structured questionnaire methods.

• Participants will undergo medical evaluations using medical history, physical exam, standard lab tests (complete blood chemistry, urinalysis, urine pregnancy test for females) and 12-lead ECG.

Exclusion Criteria:

• Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts; severe depression)

• Substance Use Disorders other than Nicotine Use Disorder and Mild Cannabis Use Disorder

• Neurological diseases; cardiovascular problems (e.g. systolic BP >140 or <95 mmHg, diastolic BP >90 mmHg, abnormal ECG); pulmonary diseases; systemic diseases (e.g. liver, renal, inflammatory)

• Cognitive impairment (<80 IQ)

• Past-month medications that increase study risk

• Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control (oral or depot contraception, IUD, condom/foam, sterilization, tubal ligation)

• Individuals unable to give informed consent will be excluded.